Ruzasvir
Code | Size | Price |
---|
TAR-T68015-1mg | 1mg | £224.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T68015-5mg | 5mg | £456.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T68015-10mg | 10mg | £622.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T68015-25mg | 25mg | £938.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T68015-50mg | 50mg | £1,259.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20°C
Images
Documents
Further Information
Bioactivity:
Ruzasvir is a novel and potent pan-genotypic inhibitor of hepatitis C virus NS5A with antiviral activity.
CAS:
1613081-64-3
Molecular Weight:
947.09
Pathway:
Microbiology/Virology|Proteases/Proteasome
Purity:
0.9701
SMILES:
FC1=C2C=3N([C@@H](OC2=CC(=C1)C=4NC(=NC4)[C@H]5N(C([C@@H](NC(OC)=O)C(C)C)=O)CCC5)C=6SC(=NC6)C7CC7)C=8C(C3)=CC(=CC8)C=9NC(=NC9)[C@H]%10N(C([C@@H](NC(OC)=O)C(C)C)=O)CCC%10
Target:
HCV Protease
References
Asante-Appiah E, et al. In Vitro Antiviral Profile of Ruzasvir, a Potent and Pangenotype Inhibitor of Hepatitis C Virus NS5A. Antimicrob Agents Chemother. 2018 Oct 24;62(11):e01280-18.
Wyles D, et al. C-CREST Part C and C-SURGE Investigators. Grazoprevir, ruzasvir, and uprifosbuvir for hepatitis C virus after NS5A treatment failure. Hepatology. 2017 Dec;66(6):1794-1804.